Welcome to our dedicated page for Ocuphire Pharma news (Ticker: OCUP), a resource for investors and traders seeking the latest updates and insights on Ocuphire Pharma stock.
The OCUP news archive on Stock Titan captures the period when Ocuphire Pharma, Inc. was a standalone clinical-stage ophthalmic biopharmaceutical company and the subsequent transition to Opus Genetics, Inc. Company press releases describe a focus on therapies for retinal and refractive eye disorders, including non-proliferative diabetic retinopathy, presbyopia, dim light vision disturbances after keratorefractive surgery, and pharmacologically induced mydriasis.
Historical OCUP news includes clinical trial milestones for APX3330, an oral small-molecule inhibitor of Ref-1 being developed for diabetic retinopathy, and Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. Releases detail Phase 2 and Phase 3 study designs, subset analyses from the ZETA-1 trial in diabetic retinopathy, and pivotal MIRA-2 and MIRA-3 results that supported FDA approval of Phentolamine Ophthalmic Solution 0.75% as RYZUMVI™ for pharmacologically induced mydriasis.
News items also track the initiation and progress of the VEGA-3 Phase 3 trial in presbyopia and the LYNX-2 Phase 3 registration trial in dim light disturbances, as well as scientific presentations at meetings such as ARVO, ASRS, Clinical Trials at the Summit, and the Retinal Imaging Biomarkers & Endpoints Summit. Corporate updates have covered financial results, collaboration and license agreements, and the eventual all-stock acquisition of Opus Genetics, Inc., after which the combined company was renamed Opus Genetics and began trading under the Nasdaq ticker "IRD."
Investors and researchers can use this OCUP news history to follow how the company’s strategy evolved from small-molecule ophthalmic drugs toward a broader portfolio that now includes adeno-associated virus-based gene therapies for inherited retinal diseases under the Opus Genetics name.
Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, announced that its CEO Mina Sooch and other executives will participate in a fireside chat on December 14, 2020, at 11am ET, hosted by Kristen Kluska of Cantor Fitzgerald. The discussion will cover 2021 data catalysts, late-stage trial designs for Nyxol and APX3330, and competitive landscapes for four ophthalmic indications. Ocuphire's pipeline includes Nyxol, entering Phase 3 trials, and APX3330, entering Phase 2 trials. Research on Ocuphire has been initiated by Cantor Fitzgerald.
Ocuphire Pharma (NASDAQ: OCUP) has initiated patient enrollment for the MIRA-2 Phase 3 trial, evaluating Nyxol® for reversing pharmacologically-induced mydriasis. The trial aims to enroll 168 patients across 12 clinical sites in the U.S., with top-line results expected by Q1 2021. Previous research indicates a strong market demand for such a drug, as 45% of surveyed patients expressed interest in a reversal drop. The MIRA-1 Phase 2b study has been accepted for publication in the journal Optometry and Vision Science.
Ocuphire Pharma has achieved notable milestones with its lead candidates, Nyxol and APX3330. The Japanese Patent Office has approved a patent for Nyxol, covering its use in daily administration until 2034. Additionally, Ocuphire received a $1.7 million NIH grant for research on APX3330, which is advancing into Phase 2 trials targeting diabetic retinopathy and diabetic macular edema. These developments indicate potential growth in their ophthalmic portfolio, enhancing market positioning and partnerships in Asia and Europe.
Ocuphire Pharma has published two significant papers on its drug candidate APX3330, highlighting its potential in treating inflammatory and angiogenic diseases. These publications, featured in Drug Discovery Today and Inflammatory Bowel Disease, indicate that Ref-1 inhibition may benefit conditions like diabetic retinopathy and chronic colitis. A Phase 2 trial, ZETA-1, is set to begin in early 2021, evaluating APX3330's efficacy in diabetic retinopathy with an enrollment goal of 100 patients. The drug aims to demonstrate improvements in retinal health and anti-inflammatory properties.
Ocuphire Pharma will participate in the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 3:30 PM. This follows their recent merger with Rexahn Pharmaceuticals and a private placement closure. Ocuphire, trading under the ticker symbol OCUP on Nasdaq, focuses on developing therapies for eye disorders. Their lead product, Nyxol® Eye Drops, targets conditions such as night vision disturbances, while the second candidate, APX3330, is aimed at retinal diseases.
Ocuphire Pharma, a clinical-stage biopharmaceutical company, announced the appointment of Susan Benton to its board of directors, effective November 5, 2020. Benton brings over 30 years of experience in life sciences, particularly in ophthalmology, with leadership roles at notable firms such as Thea Pharma and Shire. Ocuphire has also completed merger and financing transactions, marking its trading debut on the Nasdaq under the symbol OCUP. The company focuses on therapies for eye disorders, with key products including Nyxol® Eye Drops and APX3330.
Ocuphire Pharma has completed its merger with Rexahn Pharmaceuticals, transitioning to a publicly traded biopharmaceutical entity focused on ophthalmic drug development. Starting November 6, 2020, shares will trade under the symbol 'OCUP' on the Nasdaq after a 1-for-4 reverse stock split. The merger includes a $21.15 million private placement led by institutional investors, granting them approximately 86.6% ownership of the combined firm. Ocuphire aims to advance its late-stage clinical pipeline, including products targeting various eye disorders.